Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) generates a steady flow of news as a commercial-stage biopharmaceutical company focused on vaccines for infectious diseases. News coverage commonly highlights developments related to its adult hepatitis B vaccine HEPLISAV-B®, its CpG 1018® adjuvant platform, and a growing pipeline of adjuvanted vaccine candidates.
Investors and observers following DVAX news will see regular updates on financial results, including quarterly earnings releases filed via Form 8-K, where Dynavax reports HEPLISAV-B net product revenue, total revenues, and adjusted EBITDA, along with commentary on market share trends in the U.S. adult hepatitis B vaccine market. These releases often include forward-looking guidance and discussion of capital allocation decisions such as share repurchase authorizations.
Another major category of Dynavax news involves clinical and pipeline milestones. The company issues press releases on topline data from its Phase 1/2 shingles vaccine trial for Z-1018, describing immunogenicity, tolerability and head-to-head comparisons with Shingrix®. Additional updates cover progress in its plague vaccine program funded by the U.S. Department of Defense, its pandemic influenza adjuvant program using CpG 1018 with H5N1 influenza vaccine, and its investigational Lyme disease vaccine candidate.
Corporate and strategic news items include participation in healthcare investor conferences, announcements of conference calls and webcasts, and collaboration agreements. Notably, Dynavax and Vaxart announced an exclusive license and collaboration for an investigational oral COVID-19 vaccine candidate, and Sanofi has announced an agreement to acquire Dynavax through a cash tender offer and subsequent merger, subject to customary conditions.
By tracking the DVAX news feed, readers can monitor how Dynavax’s commercial performance, clinical data, collaborations and corporate transactions evolve over time. This page aggregates company press releases and related disclosures so that users can review financial updates, pipeline progress and strategic announcements in one place.
Medigen Vaccine Biologics Corporation (MVC) and Dynavax Technologies Corporation (Nasdaq: DVAX) announced the rollout of MVC-COV1901, a COVID-19 vaccine, with an initial distribution to approximately 600,000 people in Taiwan. MVC recently received emergency use authorization from the Taiwan FDA for its two-dose vaccine, which utilizes Dynavax's CpG 1018 adjuvant. The vaccine showed promising safety and efficacy in clinical trials. MVC's CEO highlighted the importance of serving Taiwan during the pandemic, while Dynavax's CEO expressed hopes for further approvals of vaccines using their adjuvant.
Dynavax Technologies (DVAX) reported Q2 2021 financial results showing significant growth. Total revenue reached $52.8 million, up from $2.7 million in Q2 2020. HEPLISAV-B net revenue was a record $13.7 million, while CpG 1018 contributed $39 million. The company announced a commercial supply agreement with Biological E for its COVID-19 vaccine candidate. Dynavax also increased its cash reserves to $345.8 million. The CDC is set to vote on a universal hepatitis B recommendation in October 2021.
Dynavax Technologies (Nasdaq: DVAX) announced on August 3, 2021, the granting of stock options to purchase 438,000 shares to 44 new employees. The options, granted on August 2, 2021, have an exercise price of $9.45 per share, aligning with the closing stock price on that date. Each option has a 7-year term and vests over three years, with one-third vesting after one year. This action complies with Nasdaq Listing Rule 5635(c)(4) aimed at incentivizing new hires.
Dynavax Technologies Corporation (NASDAQ: DVAX) is set to report its second quarter 2021 financial results on August 4, 2021, following the close of U.S. markets. A conference call will occur the same day at 4:30 p.m. ET. The company, known for its HEPLISAV-B® Hepatitis B vaccine, continues to develop novel vaccines and adjuvants, including collaborations for COVID-19 and other significant vaccines. The live webcast will be available on their investors’ website, with replay options for 30 days.
Dynavax Technologies (DVAX) announced a commercial supply agreement with Biological E. Limited for its CpG 1018 adjuvant, aimed at enhancing BE's COVID-19 vaccine candidate, CORBEVAX™. The agreement extends through 2022, covering doses manufactured under prior funding from the Coalition for Epidemic Preparedness Innovations (CEPI). In June 2021, India's Ministry of Health secured 300 million doses of CORBEVAX™. Ryan Spencer, CEO of Dynavax, expressed pride in the collaboration, while BE's Managing Director emphasized the vaccine's potential in combating the pandemic.
Dynavax Technologies Corporation (Nasdaq: DVAX) has granted nonstatutory stock options for 51,000 shares to five new employees as an inducement for employment. The options, with an exercise price of $10.23 per share, were issued on July 1, 2021, and are set to vest over three years. Each option has a 7-year term and vests one-third after one year, with the remainder vesting monthly. This action complies with Nasdaq Listing Rule 5635(c)(4) and is part of the 2021 Inducement Award Plan.
Clover Biopharmaceuticals and Dynavax Technologies have entered a commercial supply agreement for Dynavax's CpG 1018 adjuvant, intended for use in Clover's SCB-2019 COVID-19 vaccine. The agreement is valid through 2022 and includes doses manufactured under prior funding. Clover also announced an advanced purchase agreement with Gavi for up to 414 million doses of SCB-2019 via the COVAX Facility, pending regulatory approvals. The vaccine aims for a product launch by the end of 2021, following clinical trial data expected mid-year.
Clover Biopharmaceuticals has entered into a commercial supply agreement with Dynavax Technologies for the CpG 1018 adjuvant to be used in the production of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). The deal extends until the end of 2022, with doses to be delivered in 2021. Clover also announced an advanced purchase agreement with Gavi for up to 414 million doses through 2022. Pending regulatory approvals, SCB-2019 is expected to launch by the end of 2021 to supply the COVAX Facility and direct government procurement.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the appointment of John Slebir as Senior Vice President and General Counsel on June 28, 2021. To incentivize his employment, the company granted him a non-statutory stock option to purchase 300,000 shares at an exercise price of $9.29 per share, which matches the closing price on the grant date. The option has a 7-year term and vests over three years. This grant complies with Nasdaq Listing Rule 5635(c)(4) as part of Dynavax's 2021 Inducement Award Plan.
Dynavax Technologies Corporation (Nasdaq: DVAX) will have its CEO, Ryan Spencer, present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 p.m. E.T. The presentation will be accessible via webcast through the company's website's 'Events & Presentations' section.
Dynavax specializes in developing novel vaccines, with its first product HEPLISAV-B® approved in the U.S. and EU for hepatitis B prevention in adults. The company is also advancing research on vaccine adjuvants, including collaborations for COVID-19 vaccines.